Knowledge Network Node

Characteristics of drug policy and pharmacoeconomics study on rare diseasesChinese Full TextEnglish Full Text (MT)

HU Shan-lian;School of Public Health,Fudan University;

Abstract: At present,we are facing challenges in the development of rare disease drugs. The paper introduces the ethical theories of rare disease treatment,the characteristics of pharmacoeconomic evaluation on orphan drugs,the risk of reimbursement in medical insurance funds,the international experiences on the balance between the accessibility and cost containment of high-cost orphan drugs,the orphan drug list promulgated by Hong Kong SAR of China in 2019 and the status quo of orphan drugs in China. The author also analyzes the international practice from different perspectives,such as,the Orphan Drug Act(ODA)in the United States,the new concept of high specific technology introduced by National Institute Health and Clinical Excellence(NICE)in the UK,the retrospective review of pharmacoeconomics of orphan drugs by National Centre for Pharmacoeconomics(NCPE)in Ireland,the principles of orphan drug evaluation by TLV in Sweden,a special research program on the cost of orphan drugs in Turkey,and the four measures to control the cost of high-priced drugs in the Republic of Korea. The aim of this paper is to introduce international experiences for reference on the formulation of drug policies in rare diseases and development of related pharmacoeconomics in China.
  • DOI:

    10.13220/j.cnki.jipr.2019.09.002

  • Series:

    (E) Medicine & Public Health

  • Subject:

    Pharmaceutics

  • Classification Code:

    R95

Download the mobile appuse the app to scan this coderead the article.

Tips: Please download CAJViewer to view CAJ format full text.

Download: 1399 Page: 652-658 Pagecount: 7 Size: 940K

Related Literature
  • Similar Article
  • Reader Recommendation
  • Associated Author